Modality
Cell Therapy
MOA
TNFi
Target
CD123
Pathway
Tau
DMDSCD
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Dec 2029
Phase 1Current
NCT04862586
357 pts·DMD
2021-03→2026-02·Not yet recruiting
NCT04345952
892 pts·DMD
2023-08→2029-12·Active
1,249 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-231mo agoInterim· DMD
2029-12-253.7y awayInterim· DMD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Not yet…
P1
Active
Catalysts
Interim
2026-02-23 · 1mo ago
DMD
Interim
2029-12-25 · 3.7y away
DMD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04862586 | Phase 1 | DMD | Not yet recr... | 357 | NT-proBNP |
| NCT04345952 | Phase 1 | DMD | Active | 892 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Zorizumab | Beam | Approved | CD123 | |
| Rimatinib | Ventyx Bio | Phase 1 | CD20 | |
| Talatuximab | Protagonist | Phase 2 | B7-H3 |